CDH22: A Promising Drug Target and Biomarker for Prostate Cancer

Target Name: CDH22

NCBI ID: G64405

CDH22

CDH22: A Promising Drug Target and Biomarker for Prostate Cancer

Prostate cancer is the most common cancer in men, and its incidence is increasing worldwide. According to the World Health Organization (WHO), an estimated 17 million men worldwide will have prostate cancer in 2022. Prostate cancer is a complex disease that has a high mortality rate and a significant impact on quality of life. The development of new treatments and biomarkers for this disease is crucial for improving outcomes.

CDH22: A Potential Drug Target and Biomarker

The Camptotruncal D gene (CDH22) is a gene that encodes the protein PB-cadherin. PB-cadherin is a transmembrane protein that is involved in cell-cell adhesion. It plays a crucial role in the development and progression of many diseases, including cancer.

Recent studies have identified CDH22 as a potential drug target and biomarker for prostate cancer. Several studies have shown that inhibiting CDH22 can significantly reduce the growth of prostate cancer cells and their ability to invade surrounding tissue.

CDH22 as a Drug Target

CDH22 has been identified as a potential drug target for prostate cancer due to its role in cell-cell adhesion. By inhibiting the activity of CDH22, researchers have found that they can reduce the growth of prostate cancer cells and their ability to invade surrounding tissue.

One of the main mechanisms by which CDH22 contributes to the development and progression of prostate cancer is its role in the development of androgen-sensitive cancer. Androgens, such as androsterone and testosterone, are essential for the growth and development of prostate cancer. However, androgens can also stimulate the growth and development of cancer cells.

Research has shown that CDH22 is involved in the development of androgen-sensitive prostate cancer by promoting the production of androgens and inhibiting the sensitivity of cancer cells to androgens. By targeting CDH22, researchers have found that they can reduce the production of androgens and inhibit the sensitivity of cancer cells to androgens, leading to a reduction in the growth and progression of cancer cells.

CDH22 as a Biomarker

CDH22 has also been identified as a potential biomarker for prostate cancer. The ability of CDH22 to bind to and stimulate the growth of cancer cells makes it an attractive target for researchers to study the development and progression of cancer.

Research has shown that CDH22 can be used as a biomarker for prostate cancer by measuring its expression in the cells of cancer patients. Studies have shown that CDH22 expression is significantly increased in prostate cancer cells compared to normal cells. This increase in CDH22 expression has been associated with a poor prognosis for prostate cancer patients.

In addition, some studies have shown that CDH22 has been associated with the development of metastatic prostate cancer. By measuring the expression of CDH22 in the cells of metastatic prostate cancer patients, researchers have found that CDH22 expression is significantly increased compared to the cells of non-metastatic cancer patients.

Conclusion

CDH22 has been identified as a potential drug target and biomarker for prostate cancer. Its role in cell-cell adhesion and its association with the development and progression of androgen-sensitive cancer make it an attractive target for researchers to study. Further studies are needed to confirm its potential as a drug target and biomarker for prostate cancer.

Protein Name: Cadherin 22

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. PB-cadherins may have a role in the morphological organization of pituitary gland and brain tissues (By similarity)

The "CDH22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets